尼妥珠单抗联合顺铂同步放化疗治疗中晚期鼻咽癌的效果

摘要

Objective This article discusses nimotuzumab plus cisplatin concurrent radiotherapy and chemotherapy in advanced clinical effect of NPC.Methods 60 patients with advanced nasopharyngeal carcinoma patients in our hospital from January 2013~ December 2014 period treated as the object of study, were randomly divided into observation group and the control group, the control group were treated with concurrent chemoradiotherapy with cisplatin treatment, the observation group were treated with nimotuzumab plus cisplatin concurrent chemoradiation treatment, the treatment effect between the two groups of patients and incidence of adverse reactions.Results In the treatment of patients in the observation group total effective rate was 83.3%, patients in control group, the total effective rate was 46.7%,P<0.05, the difference was statistically significant.Conclusion For patients with advanced nasopharyngeal carcinoma, using nimotuzumab pluscisplatin concurrent chemoradiation treatments to help improve patient outcomes, improve the quality of life of patients with a certain value and therapeutic advantages.%目的：本文主要探讨尼妥珠单抗联合顺铂同步放化疗治疗中晚期鼻咽癌的临床效果。方法在我院2013年1月～2014年12月期间收治的中晚期鼻咽癌患者中选取60例作为此次研究对象，随机分为观察组和对照组，对照组患者采用顺铂同步放化疗治疗方式，观察组患者采用尼妥珠单抗联合顺铂同步放化疗治疗方式，比较两组患者的治疗效果和不良反应发生率。结果观察组患者治疗总有效率为83.3%；对照组患者治疗总有效率为46.7%，P＜0.05，差异具有统计学意义。结论对于中晚期鼻咽癌患者而言，采用尼妥珠单抗联合顺铂同步放化疗治疗方式，有助于提高患者的治疗效果，改善患者的生活质量，具有一定的应用价值和治疗优势。